Moderna submits Covid vaccine EUA for US adolescents
Study of nearly 2,500 young adults deemed the vaccine 100% effective for the 12-17 year-old age group
Moderna, who earlier this month initiated an application for full FDA vaccine approval in people 18 years of age and older, has now requested an emergency use authorization (EUA) for young adults aged 12-17.
“We are pleased to announce that we have submitted for an emergency use authorization for our Covid-19 vaccine with the FDA for use in adolescents in the United States,” says Stéphane Bancel, Moderna’s CEO. “We are encouraged that the Moderna Covid-19 vaccine was highly effective at preventing Covid-19 and SARS-CoV-2 infection in adolescents.”
Bancel also noted that Moderna has already applied for EUAs in Canada and the UK as well.
In a study of nearly 2,500 young adults in this 12-17 age group released in May, the Moderna vaccine was considered 100% effective in preventing Covid-19. Pfizer-BioNTech presented these same 100% efficacy findings, but for those ages 12-15.
Trending Data & Response Plans in the Cleanroom Setting
April 30th 2025Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
ABM’s Digital Solution for Good Manufacturing Practices
April 30th 2025Learn how our digital GMP solution ensures compliance with high regulatory standards, and offers faster, more accurate data access. By utilizing a mobile app for data collection and a management dashboard for task visibility and validation, it goes beyond traditional paper methods to meet growing industry needs.
